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ABSTRACT
Objective: Most pneumonia treatment guidelines
recommend that prior outpatient antibiotic treatment
should be considered when planning inpatient
antibiotic regimen. Our purpose was to study in
patients admitted for community-acquired pneumonia
the mode of continuing antibiotic treatment at the
outpatient to inpatient transition and the subsequent
clinical course.
Design: Retrospective cohort study.
Setting: Dutch PHARMO Record Linkage System.
Participants: 7323 patients aged >18 years and
hospitalised with pneumonia in the Netherlands
between 2004 and 2010.
Main study parameter: We identified all prescribed
antibiotics prior to, during and after hospitalisation. In
case of prior outpatient treatment, the continuation of
antibiotic treatment on admission was categorised as:
no atypical coverage > no atypical coverage; atypical
coverage > atypical coverage; no atypical coverage >
atypical coverage; and atypical coverage > no atypical
coverage.
Main outcome measures: Length of hospital stay,
in-hospital mortality and readmission within 30 days.
Results: Twenty-two per cent of the patients had
received prior outpatient treatment, of which 408
(25%) patients were switched on admission to
antibiotics with atypical coverage. There were no
differences in length of hospital stay, in-hospital
mortality or readmission rate between the four
categories of patients with prior outpatient treatment.
The adjusted HR for adding atypical coverage versus
no atypical coverage was 0.91 (95% CI 0.55 to 1.51)
for time to discharge. For in-hospital mortality and
readmission within 30 days, the adjusted ORs were
1.09 (95% CI 0.85 to 1.34) and 0.59 (95% CI 0.30 to
1.18), respectively.
Conclusions: This study found no association
between mode of continuing antibiotic treatment at the
outpatient to inpatient transition and relevant clinical
outcomes. In particular, adding atypical coverage in
patients without prior atypical coverage did not
influence the outcome.
INTRODUCTION
In Europe, pneumonia is the primary cause
of hospitalisation for over three million
persons per year, with mortality rates
reported between 5% and 20%.1 The major
aetiological cause of pneumonia is infection
by Streptococcus pneumoniae or Haemophilus
inﬂuenzae.2 Given this aetiology, several
European guidelines for management of
non-severe community-acquired pneumonia
(CAP) recommend β-lactam antibiotics as
ﬁrst choice empirical treatment; however, in
case of non-responsiveness to these antibio-
tics, treatment for atypical pathogens should
Strengths and limitations of this study
▪ Strength of the study is that we had the oppor-
tunity to conduct it using a nationwide database
with long-standing validity for drug and out-
comes research.
▪ Within that database, it was possible to identity a
large cohort of more than 7000 patients admit-
ted for pneumonia, and with both community
pharmacy and in-hospital pharmacy data avail-
able. This resulted in very detailed information
on routine care prescribing of antibiotic treat-
ment on admission to patients with and without
prior outpatient treatment, and the possibility to
study this in relation to major clinical outcomes.
▪ A limitation is that we were not able to evaluate
pneumonia severity as a potential confounder or
effect modifier in our multivariable analyses. On
the other hand, most treatment guidelines rec-
ommend adding atypical coverage after non-
responsiveness to β-lactam treatment for mild
pneumonia and combination therapy for severe
pneumonia. In other words, this implies that all
patients with prior β-lactam outpatient treatment
should receive atypical coverage irrespective of
disease severity. The present study does not
support this.
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be considered.2–4 In more detail, the current British
Thoracic Society (BTS) guideline recommends that
monotherapy with a macrolide may be suitable for
patients with moderate to severe CAP who have failed to
respond to an adequate course of amoxicillin before
admission, whereas the European Society of Clinical
Microbiology and Infectious Diseases (ESCMID) guide-
line suggests that for patients with no need for intensive
care admission, the choice of antimicrobial agents should
be based on considerations of allergy, intolerance and
previous use of penicillin, macrolides or quinolones. The
Dutch Working Party on Antibiotic Policy (SWAB) guide-
line recommends that for patients with mild CAP who
receive amoxicillin or penicillin as initial therapy but do
not improve within 48 h, therapy should be switched to
monotherapy with a macrolide or doxycycline. Although
studies support the strategy to add atypical coverage after
non-responsiveness to β-lactam antibiotics from a micro-
bial perspective,5 6 little is known about how this is
handled in clinical practice. For example, how is initial
inpatient treatment modiﬁed in case of patients present-
ing to the emergency department after non-
responsiveness to prior outpatient treatment? Aim of this
study is to identify patterns of antibiotic prescribing at
the outpatient to inpatient transition of patients with
CAP and to study associations between these patterns and
the subsequent clinical course.
METHODS
This is an observational study using data from the Dutch
PHARMO Record Linkage System (PHARMO RLS
founded in 1999; http://www.pharmo.nl). This database
includes data from several healthcare providers, among
which are hospital discharge records from hospital
administration systems and drug dispensing records
from community pharmacies and in-hospital pharma-
cies. Both in-hospital and community pharmacy data are
available for approximately one million individuals in
deﬁned areas of the Netherlands. The computerised
drug dispensing histories from community pharmacies
contain data on the dispensed drug, dispensing date,
type of prescriber, amount dispensed, prescribed dose
regimens and the duration of use. The in-hospital phar-
macy database includes data on inpatient medication
orders (type of drug, dose, time of administration and
duration of use). All drugs are coded according to the
Anatomical Therapeutic Chemical (ATC) Classiﬁcation.
The hospital records include detailed information con-
cerning the primary (mandatory) and secondary
(optional) discharge diagnoses, procedures, and dates
of hospital admission and discharge. All diagnoses are
coded according to the International Classiﬁcation of
Diseases, Ninth Revision, Clinical Modiﬁcation
(ICD-9-CM). Permission to conduct the study was
obtained from the PHARMO Institute for Drug
Outcomes Research. Ethics approval was not applicable
because all data in the PHARMO RLS are anonymous.
Study patients
We constructed a cohort of participants of age 18 years
and older, with an episode of hospitalisation for CAP
between 1 January 2004 and 31 December 2010.
Episodes of pneumonia were selected based on ICD-9
codes 481–487. Patients were included in the study
cohort if they had in-hospital medication data available,
had a history of at least 12 months in PHARMO RLS
before the hospitalisation for pneumonia, were dis-
charged to their home and had a follow-up in PHARMO
RLS of at least 3 months after hospitalisation or in case
of death, a follow-up until date of decease. If a patient
experienced two or more episodes of pneumonia less
than 30 days apart, only the ﬁrst episode was selected.
For each patient selected, all prescribed medications
during hospital stay, and in the year prior to and 2 weeks
after hospitalisation were captured.
Clinical characteristics
For all patients, we retrieved age and gender, and
deﬁned the following comorbidities by means of dis-
pensed medication and/or hospitalisations in the year
prior to the studied episode of pneumonia: pulmonary
disease (two or more dispensations for inhalation medi-
cation), diabetes (two or more dispensations for insulin
or oral glucose-lowering drugs or hospitalisation with
ICD-9 codes 249-250), congestive heart failure (two or
more dispensations for digoxin together with a diuretic
or hospitalisation with ICD-9 code 428), cerebrovascular
accident (hospitalisation with ICD-9 codes 430-438).
Furthermore, use of proton-pump inhibitors and corti-
costeroids was assessed (two or more dispensations in
the year prior to the hospitalisation for pneumonia).
Antibiotic usage
All prescribed antibiotics (ATC J01) in the 14 days
before, during and after hospitalisation were identiﬁed
at the patient level. Based on whether or not the patient
had received antibiotic treatment in the 2 weeks prior to
hospitalisation, patients were classiﬁed as ‘with’ or
‘without’ prior outpatient treatment. For patients who
had received prior outpatient antibiotic treatment, the
outpatient antibiotic regimen closest to the date of hos-
pitalisation was identiﬁed. The antibiotic regimen pre-
scribed at the day of hospitalisation was considered the
initial inpatient regimen. In case of prior outpatient
treatment, the transition from outpatient to inpatient
antibiotic regimen was categorised as: no atypical cover-
age > no atypical coverage; atypical coverage > atypical
coverage; no atypical coverage > atypical coverage; and
atypical coverage > no atypical coverage. Tetracyclines,
macrolides and quinolone antibiotics were considered
antibiotic coverage of atypical pathogens. For all
patients, subsequent modiﬁcations of antibiotic therapy
during hospital stay were assessed with a modiﬁcation
deﬁned as a change of agent or combination of agents
(eg, different regimen). Dose adjustments or adjustment
of administration route were not considered. Finally, the
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total duration (in days) of antibiotic therapy was calcu-
lated for all patients (inpatient plus outpatient therapy).
Clinical course
The following items were scored for each patient as
descriptor of the clinical course: number of modiﬁca-
tions of antibiotic treatment during hospital stay, length
of hospital stay (in days), in-hospital mortality, and
readmission within 30 days from discharge.
Data analysis
The SPSS statistical package (V.20.0.0.1 for Mac) was
used for the statistical analyses. Continuous data were
expressed as the mean±SD or as the median (IQR)
where appropriate. Sankey plots were constructed to
visualise patterns of continuation of antibiotic treatment
at the outpatient to inpatient transition. Multivariable
regression analyses were conducted to examine whether
mode of transition (four categories; see above) was asso-
ciated with time to discharge (Cox regression),
in-hospital death (logistic regression) or readmission
(logistic regression). All patient characteristics were
included in the regression models as potential confoun-
ders. Sensitivity analyses comprised the restriction to
patients who were on outpatient treatment for more
than 2 days before hospital admission and exclusion of
patients who received outpatient antibiotics unusual in
the treatment of CAP in primary care (cotrimoxazole,
nitrofurantoin and quinolone antibiotics).7 Signiﬁcance
was set at p<0.05 for all tests.
RESULTS
The total study population comprised 7323 patients hos-
pitalised for CAP of which 1613 (22%) had received
prior outpatient antibiotic treatment. The mean age of
the population was 64±25 years and 47% of the patients
were male. Pulmonary disease, corticosteroid use and
proton-pump inhibitor use was more prevalent in
patients with prior outpatient treatment (table 1).
The majority of patients who received prior outpatient
antibiotics had been prescribed amoxicillin/clavulanic
acid (38%), followed by doxycycline (17%) and amoxi-
cillin (14%). Amoxicillin/clavulanic acid was also the
most prescribed initial inpatient antibiotic regimen.
Table 2 shows the top 10 initial inpatient antibiotic regi-
mens for patients with and without prior outpatient
treatment. The median total duration of antibiotic treat-
ment (inpatient plus outpatient) was 11 (IQR 8–15)
days for the complete cohort, 15 (IQR 11–20) days for
patients who received prior outpatient treatment and 10
(IQR 7–13) days for patients admitted without prior out-
patient treatment.
Comparing the outpatient antibiotic regimens with
the initial inpatient regimens revealed that 38% of the
patients continued with no atypical coverage and 16% of
the patients continued with atypical coverage, whereas
25% of the patients were switched to an antibiotic
regimen covering atypical pathogens, and 21% of the
patients vice versa. Figure 1 shows the distribution of
transitions between outpatient regimens and initial
inpatient regimens. Twenty-three per cent of the patients
were prescribed exactly the same antibiotic regimen as
they had received before hospitalisation.
In table 3, the clinical course is shown for patients
with and without prior outpatient treatment. Overall,
median length of hospital stay was, although strictly stat-
istically different, 7 days for both patients with and
without prior outpatient treatment (median 7 (4–11) vs
7 (5–12) days; p=0.008). The frequency of any change in
the initial antibiotic treatment was lower for patients
without prior outpatient treatment (39% vs 43%;
p=0.009). There was no difference in in-hospital mortal-
ity (6.6% vs 7.7%; p=0.10).
Within the patients with prior outpatient treatment,
there were no differences in length of hospital stay,
Table 1 Patient characteristics of patients with and
without prior outpatient treatment
Prior
outpatient
treatment
1613 (100%)
No prior
outpatient
treatment
5710 (100%) p Value
Age (mean±SD) 64±25 63±25 0.62
Male gender 753 (47) 2430 (43) 0.003
Pulmonary
disease
720 (45) 2141 (38) <0.001
Diabetes 53 (3) 194 (3) 0.83
Heart failure 114 (7) 335 (6) 0.08
CVA 15 (1) 87 (2) 0.07
PPI use 594 (37) 1705 (30) <0.001
Corticosteroid use 474 (29) 1305 (23) <0.001
Data are presented as number (%), unless otherwise stated.
CVA, cerebrovascular accident; PPI, proton-pump inhibitor.
Table 2 Initial inpatient antibiotic regimens for patients
with and without prior outpatient treatment
Prior
outpatient
treatment
N=1613
(100%)
No prior
outpatient
treatment
N=5710
(100%)
Amoxicillin/clavulanic acid 576 (36) 2456 (43)
Amoxicillin 78 (5) 563 (10)
Amoxicillin/clavulanic acid
+ciprofloxacin
134 (8) 473 (8)
Cefotaxime 118 (7) 345 (6)
Amoxicillin+ciprofloxacin 62 (4) 195 (3)
Benzylpenicillin+
ciprofloxacin
37 (2) 172 (3)
Cefuroxime 27 (2) 125 (2)
Moxifloxacin 44 (3) 124 (2)
Ciprofloxacin 57 (4) 111 (2)
Clarithromycin 42 (3) 92 (2)
Data are presented as number (%).
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readmission rate or in-hospital mortality between the
four identiﬁed categories (table 3). In the multivariable
regression analyses (reference category: no atypical
coverage > no atypical coverage), none of the transition
categories were associated with time to hospital dis-
charge (adjusted HRs 0.95 (95% CI 0.77 to 1.17), 1.09
(0.85 to 1.34) and 1.03 (0.82 to 1.28), respectively),
in-hospital mortality (adjusted ORs 1.16 (0.66 to 2.02),
0.91 (0.55 to 1.51) and 0.95 (0.58 to 1.56), respectively),
and readmission rate (adjusted ORs 0.79 (0.39 to 1.61),
0.59 (0.30 to 1.18) and 0.72 (0.39 to 1.35), respectively).
For the latter two models, the Hosmer-Lemeshow good-
ness of ﬁt test result and the area under the receiver
operating characteristic curve (AUC) were p=0.23 (AUC
0.721) and p=0.99 (AUC 0.695). When the analyses were
restricted to patients who were on antibiotic treatment
for more than 2 days before hospital admission, this did
not result in any signiﬁcant changes in the calculated
ORs. The same applies to the exclusion of patients with
prior outpatient antibiotics unusual for the treatment of
CAP in primary care (data not shown).
DISCUSSION
This large observational study in over 7200 patients with
CAP showed a large variation in outpatient and initial
inpatient antibiotic regimens. In only a quarter of the
patients with prior outpatient treatment, atypical cover-
age was added to the initial inpatient therapy, but there
was no association between mode of continuing of anti-
biotic treatment at the outpatient to inpatient transition
and relevant subsequent clinical outcomes, like length
of hospital stay, in-hospital mortality rate or readmission
rate.
In general, protocols for empirical antimicrobial treat-
ment are based on information about the most likely
pathogens involved, prevalence of resistance in these
pathogens and risks of unfavourable outcome when
therapy is not appropriate. The latter is reﬂected in
most guidelines by suggesting broader spectrum antibio-
tics in severe pneumonia.2 3 Besides this, responsiveness
to antibiotic treatment could act as a ‘test therapeutique’
or indirect microbiological examination, and can be
used in addition to guide the antibiotic treatment
regimen. The latter is, for example, incorporated in the
British and Dutch pneumonia treatment guidelines by
recommending that for patients with moderate to severe
CAP and who received amoxicillin or penicillin as initial
therapy but do not improve within 48 h, therapy should
be switched to monotherapy with a macrolide or doxy-
cycline; for patients with moderate to severe CAP and
failure to improve despite 48 h treatment with a β-lactam
antibiotic, an adequate dosage without evidence of
abnormal absorption or non-compliance coverage for
Figure 1 Sankey plot of antibiotic treatment at the outpatient to inpatient transition (n=1613 transitions). Left side: the top-10
outpatient regimens. Right side: initial inpatient regimens.
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Legionella sp should be added.3 4 That patients with
pneumonia are hospitalised after prehospital antibiotic
treatment is a common scenario with percentages
reported in the recent literature between 17% and
26%.5 6 8 9 In the present study, 22% of the patients had
received antibiotic treatment before hospital admission.
To our knowledge, this study is the ﬁrst study to show
how antibiotic prescribing at the time of hospitalisation
for pneumonia is affected by whether or not patients
received prior outpatient treatment. The distribution of
initial inpatient treatment regimens was very similar for
patients with or without prior outpatient treatment. This
suggests that choice of initial inpatient treatment is not
to a great extent inﬂuenced by prior outpatient treat-
ment. The Sankey plot also illustrated that there was no
obvious pattern of adding atypical coverage in case of
prior outpatient β-lactam treatment. But what are the
clinical consequences? Overall, the present study showed
no major impact of antibiotic prescribing practice at the
outpatient to inpatient transition, neither on time to
hospital discharge nor on in-hospital mortality and need
for readmission. The median duration of hospital stay
was 7 days in all categories identiﬁed. Although micro-
bial examinations have conﬁrmed increased prevalence
of atypical organisms in patients hospitalised after prior
outpatient β-lactam treatment,5 6 the present study does
not extend this ﬁnding towards major clinical conse-
quences when atypical pathogens are not covered in the
initial inpatient antibiotic treatment. In the present
study, in 38% of the patients, β-lactam monotherapy was
continued at admission without affecting prognosis.
Possibly some atypical organisms are self-limiting irre-
spective of antibiotic treatment or alternatively, the
current standard of care in hospitals timely modiﬁes
antibiotic treatment when necessary. The high incidence
of modiﬁcation of antibiotic treatment later during hos-
pital stay in patients with prior outpatient treatment (on
average 43%) could support such an explanation.
Systematically searching for Legionella pneumophila, for
example, might have provided a sufﬁcient safety net to
compensate not initiating combination therapy in the
non-severely ill patients (assuming that combination
therapy has been initiated in all patients with severe
CAP). Such strategy corresponds to a large extent to the
very recent randomised study of Garin et al10 where
patients with Pneumonia Severity Index (PSI) category
IV pneumonia had delayed clinical stability with
β-lactam monotherapy, but monotherapy was not infer-
ior to combination therapy (β-lactam plus macrolide) in
patients with PSI category I–III. Although patients with
administration of any antibiotic for more than 24 h
before admission were excluded from that study, its ﬁnd-
ings might thus extend to patients with prior outpatient
treatment. Unfortunately, in the present study we could
not explore this further because clinical information
regarding disease severity at the time of admission was
not available in the database as was the percentage of
patients with atypical pathogens. Nonetheless, the
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current recommendation to add atypical coverage in all
patients with prior β-lactam outpatient therapy is not
supported by the present study ﬁndings.
The present study also illustrates that when measuring
the total duration of antibiotic exposure in patients with
pneumonia, data should not be limited to outpatient or
inpatient prescription data only. The median treatment
duration was 11 days for all patients (n=7323) and
15 days for patients who received prior outpatient treat-
ment. For comparison: the median duration of hospital
stay was 7 days. This means that the total antibiotic
selective pressure of an episode of pneumonia is higher
than only in-hospital exposure. Further, the recom-
mended total duration of antibiotic treatment for pneu-
monia of 7–10 days was exceeded in more than half of
the patients. The ﬁnding that median duration was
3 days longer than the length of hospital stay in patients
without prior outpatient treatment also indicates that a
large proportion of patients are being prescribed anti-
biotic treatment after discharge. Further research is def-
initely needed to address whether this holds any clinical
beneﬁts or not. Three days of antibiotic therapy has
proven safe in mild to moderate severe CAP.11
Strength of the study is that we had the opportunity to
conduct it using a nationwide database with long-
standing validity for drug and outcomes research.12 13
Within that database it was possible to identity a large
cohort of patients with both community pharmacy and
in-hospital pharmacy data available. However, there are
also limitations in our study that need to be addressed.
First, as discussed before, we were not able to assess
pneumonia severity as a potential confounding factor,
because detailed clinical information from the time of
presentation at the emergency department was not avail-
able in the database. It is, therefore, not possible to
exclude that mode of transition of antibiotic treatment
is associated with clinical outcome in speciﬁc disease
severity categories (eg, PSI categories I–III vs IV–V).
Second, the reason for hospital referral was not avail-
able. It cannot be ruled out that factors other than non-
responsiveness to antibiotic treatment were reason for
referral in some patients. Finally, patients with pneumo-
nia and their comorbidities were identiﬁed based on
coded hospital discharge diagnoses and drug dispensing
records. In general, this could introduce bias due to mis-
classiﬁcation. However, previous studies from the
Netherlands showed sufﬁcient sensitivity and a high posi-
tive predictive value of 88% for ICD-9-CM coded hos-
pital discharge diagnoses of CAP in hospital
administration systems.14 15 As data in the PHARMO
RLS do also come from these systems, we consider that
these results also apply to our present study data. The
applied prescription-based proxies for comorbidities
have also been validated in patients with pneumonia
and showed varying robustness.16 The proxies for pul-
monary disease and diabetes were reliable but the per-
formance for congestive heart failure was modest. By
combining the prescription proxies with hospital
discharge diagnoses, we expect to have improved the val-
idity of the identiﬁcation of the comorbidities.
In conclusion, this study showed a large variation in
antibiotic prescribing practice for CAP. Although the
recommendation from guidelines to add atypical cover-
age after non-responsiveness to β-lactam treatment
(and vice versa) had not been followed in many
patients, there was no association with subsequent clin-
ical outcome. Additional research is warranted for the
observation that total duration of antibiotic treatment
in daily practice exceeds the recommended duration by
many days.
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